ProSemble Ltd

Active
Health services
SEIS
London, UK
Company number:
14353870
Founded:
2022-09-13
Stage
MVP
Team Size
3
Investment Metrics
Targeted
$400,000
Minimum Investment Amount
$2

ProSemble is a King's College laboratory-based start-up. Dr Julien Bergeron (ProSemble’s CEO/CSO and a senior lecturer in biophysics/biomedicine  and the leader of the Bergeron Laboratory at King’s College ) has discovered a protein that binds medicine disbursed during later stages of cancer treatment (particularly,  in breast cancers) that takes the medicine directly to the tumour for its release to be triggered with a specific chemical reaction. ProSemble biotech and AI innovation does not deal with new anti-cancer drugs but with a way  currently prescribed medicine, such as Doxorubicin, is administered, which minimises or even eliminates side effects.


ProSemble is a B2B company that will  sell or license its modifications and supporting AI to pharma.  The IP has been filed in the USA by King’s College (that is taking a stake in the company in lieu of contributing the IP back to ProSemble). The AI module has already been coded in Python by Marek Oleksiewicz, ProSemble’s CTO, and is currently being fine-tuned. ProSemble has started initial talks with pharma (Takeda, AstraZeneca) and will progress to LOIs upon completing the requested experiments re results in tox assay in mice.

 

ProSemble’s initial focus is on breast cancer and Doxorubicin. Once the breast cancer market is covered (a multi-billion-dollar industry) the same tech (with some relatively simple adjustments)  can be applied to other cancers and diseases where targeted delivery of medicine is paramount. We will then  also look at acquiring rights to drugs that failed clinical trials as believe our biotech and AI know-how can be a difference between them failing or passing clinical trials.

 

ProSemble is looking to raise $400,000  to employ two full-time research assistants to complete the research requested by Takeda and other pharma, procure necessary reagents,  fine-tune the AI  and expand business development/sales activities with pharma, which will be initially undertaken by Julien Bergeron and Inna Zhuranskaya (CFO/Head of Business Development).

Puzzled about the project? Ask away!
For further information, please reach out to the Startup directly.

Curious About This Endeavour?

Exploring new horizons? Dive into the depths of knowledge with us. Feel free to reach out – Your questions fuel our journey.